Frequently Asked Questions
The market is segmented based on , By Types (Congenital NCL, Infantile NCL, Late Infantile NCL and Adult NCL), Drugs (Cerliponase Alfa, Valproic Scid, and Levetiracetam), Therapy (Occupational Therapy and Physical Therapy), Treatment (Medication and Supportive Care), Route of Administration (Oral and Parenteral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), End Users (Hospitals, Homecare, Specialty Clinics, and Others) – Industry Trends and Forecast to 2030.
.
The Global Batten Disease Treatment Market size was valued at USD 41.39 USD Million in 2022.
The Global Batten Disease Treatment Market is projected to grow at a CAGR of 5.4% during the forecast period of 2023 to 2030.
The major players operating in the market include Abeona Therapeutics, Alexion Pharmaceuticals, Amicus Therapeutics, Lysogene, Biogen, BioMarin Pharmaceutical, Denali Therapeutics, Dimension Therapeutics, Edison Pharmaceuticals, GeneTx Biotherapeutics LLC, Orchard Therapeutics, Passage Bio, Novartis, Teva Pharmaceuticals Industries, Zydus Cadila, Mylan, Regenxbio.
The market report covers data from the U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina and rest of South America.
